🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 11 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 18/03/2019 | 188,00 | 189,21 | 185,53 | 187,48 | -0,32% | 1,96% | 1.554.100 |
| 15/03/2019 | 186,88 | 189,35 | 186,37 | 188,09 | +1,06% | 1,59% | 2.768.600 |
| 14/03/2019 | 185,62 | 186,66 | 184,45 | 186,11 | +0,24% | 1,19% | 785.700 |
| 13/03/2019 | 183,37 | 186,78 | 182,21 | 185,66 | +1,69% | 2,49% | 1.202.300 |
| 12/03/2019 | 181,15 | 183,23 | 179,85 | 182,57 | +1,14% | 1,87% | 1.545.300 |
| 11/03/2019 | 177,94 | 180,56 | 177,78 | 180,52 | +1,84% | 1,56% | 1.350.700 |
| 08/03/2019 | 177,26 | 177,62 | 173,59 | 177,26 | -0,76% | 2,27% | 1.451.500 |
| 07/03/2019 | 181,36 | 181,83 | 177,45 | 178,61 | -1,38% | 2,42% | 1.432.900 |
| 06/03/2019 | 188,18 | 188,70 | 180,56 | 181,11 | -3,56% | 4,33% | 1.381.000 |
| 05/03/2019 | 190,16 | 190,51 | 187,52 | 187,80 | -1,18% | 1,57% | 1.409.100 |
| 04/03/2019 | 193,03 | 193,89 | 186,71 | 190,04 | -1,10% | 3,72% | 1.208.600 |
| 01/03/2019 | 189,95 | 192,69 | 189,28 | 192,16 | +1,81% | 1,80% | 887.600 |
| 28/02/2019 | 189,74 | 190,04 | 188,23 | 188,75 | -0,56% | 0,95% | 1.194.700 |
| 27/02/2019 | 187,97 | 189,87 | 186,44 | 189,81 | +0,47% | 1,82% | 633.200 |
| 26/02/2019 | 186,26 | 189,99 | 184,89 | 188,92 | +1,39% | 2,74% | 1.478.000 |
| 25/02/2019 | 186,74 | 188,10 | 185,63 | 186,33 | +0,31% | 1,32% | 1.268.800 |
| 22/02/2019 | 184,33 | 185,84 | 182,94 | 185,76 | +1,47% | 1,57% | 1.027.400 |
| 21/02/2019 | 187,70 | 188,12 | 182,16 | 183,06 | -2,54% | 3,18% | 1.087.000 |
| 20/02/2019 | 186,06 | 188,64 | 185,65 | 187,84 | +0,52% | 1,61% | 1.066.300 |
| 19/02/2019 | 187,90 | 189,09 | 185,83 | 186,86 | -0,64% | 1,73% | 1.823.700 |
| 15/02/2019 | 185,67 | 188,56 | 185,67 | 188,07 | +1,27% | 1,56% | 1.408.200 |
| 14/02/2019 | 184,52 | 186,84 | 183,53 | 185,72 | +0,25% | 1,79% | 917.800 |
| 13/02/2019 | 185,00 | 186,25 | 184,35 | 185,25 | +0,67% | 1,03% | 1.244.500 |
| 12/02/2019 | 181,44 | 184,30 | 181,44 | 184,01 | +1,37% | 1,58% | 1.316.600 |
| 11/02/2019 | 182,05 | 182,17 | 178,40 | 181,53 | +0,10% | 2,07% | 2.037.000 |
| 08/02/2019 | 178,76 | 181,45 | 178,76 | 181,34 | +0,64% | 1,50% | 980.600 |
| 07/02/2019 | 181,50 | 182,59 | 178,99 | 180,18 | -1,21% | 1,98% | 1.462.500 |
| 06/02/2019 | 193,00 | 193,00 | 182,06 | 182,39 | -2,48% | 5,67% | 1.915.700 |
| 05/02/2019 | 185,81 | 190,74 | 185,44 | 187,02 | -0,51% | 2,85% | 1.643.500 |
| 04/02/2019 | 189,19 | 189,28 | 184,49 | 187,98 | -1,85% | 2,53% | 1.482.300 |